Single-inhaler combination therapy for asthma: A review of cost effectiveness

PharmacoEconomics

Volumn 24, Issue 10, 2006, Pages 971-988

  Akazawa, Manabu ^a   Stempel, David A ^b  

^a IL   (United States)

^b Infomed Northwest   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL;

ASTHMA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ACETATES; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS; QUINOLINES;

EID: 33749335680     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624100-00005     Document Type: Review

References (58)

1. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms. Lancet 1994; 334: 219-24
2. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-8
3. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of inhaled salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-73
4. Ind PW, Negro RD, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003; 97: 555-62
5. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-11
6. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-7
7. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97: 234-41
8. Nelson H, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-95
9. NIH. Guidelines for the diagnosis and management of asthma. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, 1997 Apr. NIH publication no. 97-4051
10. Global strategy for asthma management and prevention. National Institutes of Health and National Heart, Lung and Blood Institute, Revised 2002 [online]. Available from URL: http://www.ginasthma.com [Accessed 2006 Apr 16]
11. Masoli M, Holt S, Weatherall M, et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004; 23: 552-8
12. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001 Aug 4; 323 (7307): 253-6
13. NHLBI. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Asthma Education Program, National Heart, Lung and Blood Institute, 1991 Aug. Publication no. 91-3042
14. Jarjour N, Laviolette M, Moore W, et al. Control of airway inflammation and remodeling during a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC): comparison with higher dose fluticasone propionate (FP) alone [abstract]. Am J Respir Crit Care Med 2004; 169 (7): A451
15. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105: 1108-16
16. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50μg and fluticasone propionate 250μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527-34
17. Persson U, Ghatnekas O. Cost-effectiveness analysis of inhaled corticosteroids in asthma: a review of analytical standards. Respir Med 2003; 97: 1-11
18. Stempel DA, Fuhlbrigge AL. Defining the responder in asthma therapy. J Allergy Clin Immunol 2005; 115: 466-9
19. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ 2002; 325: 891-4
20. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs fluticasone propionate 100μg in adults and adolescents with asthma III: results. Pharmacoeconomics 1999; 16 Suppl. 2: 15-21
21. Palmqvist M, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250μg vs fluticasone propionate 250μg in adults and adolescents with asthma IV: results. Pharmacoeconomics 1999; 16 Suppl. 2: 23-8
22. Pieters WR, Lundbäck B, Sondhi S, et al. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500μg vs fluticasone propionate 500μg in patients with corticosteroid-dependent asthma v: results. Pharmacoeconomics 1999; 16 Suppl. 2: 29-34
23. Andersson F, Ståahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study. Respir Med 2001; 95 (6): 505-12
24. Jönsson B, Berggren F, Svensson K, et al. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respir Med 2004; 98 (11): 1146-54
25. Price D, Haughney J, Lloyd A, et al. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Curr Med Res Opin 2004; 20 (10): 1671-9
26. Brüggenjürgen B, Selim D, Kardos P, et al. Economic assess-ment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005; 23 (7): 723-31
27. Lundbäck B, Jenkin C, Price MJ, et al. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250μg twice daily and budesonide 800μg twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000; 94 (7): 724-32
28. Sheth K, Borker R, Emmett A, et al. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20 (13): 909-18
29. Pieters WR, Wilson KK, Smith HCE, et al. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treat Respir Med 2005; 4 (2): 129-38
30. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22 (12): 815-25
31. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109: 433-9
32. O'Connor RD, O'Donnell JC, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121: 1028-35
33. Balkrishnan R, Nelsen LM, Kulkarni AS, et al. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J Asthma 2005 Feb; 42 (1): 35-40
34. Aubier M, Pieters WR, Schlösser NJJ, et al. Salmeterol/fluticasone propionate (50/500μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-84
35. Ind PW, Haughney J, Price D, et al. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004; 98: 464-75
36. Buhl R, Kardos P, Baare A, et al. Adjustable dosing with budesonide/formoterol in asthma maintains HRQL at a lower drug load than fixed dosing. Curr Med Res Opin 2004; 20: 1209-20
37. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250μg twice daily is more effective than budesonide 800μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715-23
38. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short acting β2 agonists alone. Am J Respir Crit Care Med 2001; 164: 759-63
39. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112: 29-36
40. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005; 99: 1263-7
41. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245-51
42. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226-35
43. The Childhood Asthma Management Program Research Group. The long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343: 1054-63
44. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet 2003; 361: 1071-6
45. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004; 170 (8): 836-44
46. Fitzgerald JM, Boulet LP, Fellows RMA. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27: 393-406
47. Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004; 46: 398-412
48. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352: 1519-28
49. National Compensation Survey. Occupational wages in the United States, July 2004 [online]. Available from URL: http://www.bls.gov/ncs/ocs/sp/ncbl0727. pdf [Accessed 2005 Sep 9]
50. Buxton M, Sullivan SD, Andersson LF, et al. Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. Eur Respir J 2004; 24: 568-74
51. Sullivan SD, Buxton M, Andersson LF, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112 (6): 1229-36
52. Boushey HA. Daily inhaled corticosteroid treatment should not be prescribed for mild persistent asthma. Am Rev Respir Dis 2005; 172: 412-4
53. Lim S, Jatyakanon A, Gordon D, et al. Comparison of high dose inhaled steroids, low dose inhaled steroids plus theophylline, and low dose inhaled corticosteroids alone in chronic asthma in general practice. Thorax 2000; 55: 837-41
54. Price DB, Hernandez D, Magyar P, et al. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-6
55. Yildirim Z, Ozlu T, Bulbul Y, et al. Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma. Respirology 2004; 9: 243-8
56. Fitzgerald JM, Becker A, Sear MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-6
57. Harrison TW, Osborn J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomized controlled trials. Lancet 2004; 363: 271-5
58. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-36